RESUMO
BACKGROUND: colorectal cancer (CRC) is the second leading cause of cancer and cancer-related death in the world. Noninvasive biomarkers for early diagnosis of CRC are highly demanded. OBJECTIVE: The up-regulation of specific microRNAs (miRNAs) in serum has been considered a promising biomarker of CRC and miR-24-2 may be a potential biomarker in the diagnosis the progression of CRC. METHODS: Sixty-eighty healthy subjects and 228 CRC patients were divided into six groups: control group, CRC 0, CRC I, CRC II, CRC III, CRC IV and CRC V. Serum level of miR-24-2 was measured by real-time qPCR. Serum lipid profiles and oxidative-related molecules were also measured. RESULTS: Serum levels of miR-24-2 in CRC patients were significantly higher than healthy subjects (p< 0.05). In addition, the expression level of the miR-24-2 was decreased with the progression of CRC and reached the lowest level in CRC V. Spearman Rank Correlation analysis showed that miR-24-2 level was negatively related to the levels of superoxide dismutase (SOD) and reduced glutathione (GSH), aspartate transaminase (AST), alanine transaminase (ALT), cholesterol and triglyceride (p< 0.05). CONCLUSIONS: Serum miR-24-2 is a potential negative biomarker in the diagnosis of the progression of CRC patients and associated with biochemical indices.
Assuntos
Biomarcadores Tumorais/sangue , Neoplasias Colorretais/sangue , Neoplasias Colorretais/genética , MicroRNAs/sangue , Idoso , Biomarcadores Tumorais/genética , Neoplasias Colorretais/patologia , Progressão da Doença , Feminino , Humanos , Masculino , MicroRNAs/genética , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Reação em Cadeia da Polimerase em Tempo RealRESUMO
Although radical nephrectomy alone is widely accepted as the standard of care in localized treatment for renal cell carcinoma (RCC), it is not sufficient for the treatment of metastatic RCC (mRCC), which invariably leads to an unfavorable outcome despite the use of multiple therapies. Currently, sequential targeted agents are recommended for the management of mRCC, but the optimal drug sequence is still debated. This case was a 57-year-old man with clear-cell mRCC who received multiple therapies following his first operation in 2003 and has survived for over 10 years with a satisfactory quality of life. The treatments given included several surgeries, immunotherapy, and sequentially administered sorafenib, sunitinib, and everolimus regimens. In the course of mRCC treatment, well-planned surgeries, effective sequential targeted therapies and close follow-up are all of great importance for optimal management and a satisfactory outcome.
RESUMO
The effect of praziquantel on S. japonicum mother sporocysts, daughter sporocysts and cercariae was studied. At concentrations of 3 X 10(-7), 3 X 10(-6) and 3 X 10(-5) M and treatment times of 24 or 48 h, mother and daughter sporocysts and young cercarial embryos were not affected but nearly mature cercariae were killed and dissociated. The resistance of young cercariae could support the suggestion that the primitive cercarial epithelium arises from the sporocyst tegument. Treatment with praziquantel always stopped cercarial emission; this cessation lasted for a few days with the lowest concentration and for up to 25 d with the highest. The duration of treatment slightly affected the pattern of reappearance of cercariae but markedly affected the long-term reduction in numbers. Free cercariae treated with praziquantel lost their tails in 10 to 60 min, depending on the concentration.
Assuntos
Praziquantel/farmacologia , Schistosoma japonicum/efeitos dos fármacos , Animais , Relação Dose-Resposta a Droga , Larva/efeitos dos fármacos , Caramujos/parasitologia , Fatores de TempoRESUMO
Although radical nephrectomy alone is widely accepted as the standard of care in localized treatment for renal cell carcinoma (RCC), it is not sufficient for the treatment of metastatic RCC (mRCC), which invariably leads to an unfavorable outcome despite the use of multiple therapies. Currently, sequential targeted agents are recommended for the management of mRCC, but the optimal drug sequence is still debated. This case was a 57-year-old man with clear-cell mRCC who received multiple therapies following his first operation in 2003 and has survived for over 10 years with a satisfactory quality of life. The treatments given included several surgeries, immunotherapy, and sequentially administered sorafenib, sunitinib, and everolimus regimens. In the course of mRCC treatment, well-planned surgeries, effective sequential targeted therapies and close follow-up are all of great importance for optimal management and a satisfactory outcome.